The Latest Cardiac and Vascular News
Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program Highlights Mavacamten for Hypertrophic Cardiomyopathy (HCM) EXPLORER-HCM Data Presented at the […]
SAN FRANCISCO, Nov. 05, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended September 30, 2020. Third Quarter 2020 Summary Revenue of $71.9 million 31.6% increase compared […]
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results […]
EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort – ENHANCE-IT study of MAT9001 against Vascepa® fully enrolled with topline data anticipated Q1 2021; Phase 3 program on track to initiate H1 2021 – – Management to host conference call today, Friday, November 6th, at 8:30 a.m. ET – BEDMINSTER, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, […]
Record Quarterly Revenue of $24.0 Million in Q3 2020, up 172% Year over Year and up 39% from Q2 2020 Adjusted EBITDA Positive in last 2 months of Q3. Expect to be Significantly Adjusted EBITDA positive in 2021 Revenue Growth in 2021 expected in excess of 100% Raised $48.9 million, […]
Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for […]
Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque […]
Conference Call Scheduled for Today, November 4, 2020, at 3:30 PM CT (4:30 PM ET) Revenues of $60.5 million increased 42% sequentially and decreased 6.1% compared to last year Net loss was $2.1 million, or $0.05 per basic and diluted share Management provides fiscal 2021 second quarter revenue guidance of […]
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2020 on November 13, 2020 Enrollment Completed in […]
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA® (icosapent ethyl) Approval and Commercialization in Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the […]
